ArticleTranslational cancer research2025
Activated RARα counteracts the effects of TACC1v25 on the differentiation and invasion of head and neck squamous cell carcinoma.
Article in Translational cancer research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transforming acidic coiled-coil containing protein 1 (TACC1) is a key regulator of cellular differentiation, growth, and gene regulation. Despite the known interaction between full-length TACC1 and retinoic acid receptor alpha (RARα), the relationship between the short-form TACC1 variant 25 (TACC1v25) and RARα in head and neck squamous cell carcinomas (HNSCCs) remains unclear. This study aimed to evaluate the value of TACC1v25 on differentiation and invasion in HNSCC and its correlation with RARα. Methods: We analyzed the interaction between TACC1v25 and RARα by co-immunoprecipitation (Co-IP). The effects of TACC1v25 associated with RARα on the differentiation and invasion in HNSCC were assessed by western blot and transwell assays. RNA sequencing (RNA-seq) profiling and orthotopic xenograft modeling further validated the results. Results: TACC1v25 physically interacted with RARα. A portion of TACC1v25 and RARα was found at the same loci both in the nucleus and cytoplasm. After all-trans-retinoic acid (ATRA) treatment, TACC1v25 increased in the cytoplasm, whereas RARα increased in the nucleus (P<0.05). Overexpression of TACC1v25 significantly upregulated differentiation-related proteins in Cal27 and Fadu cells; however, ATRA treatment counteracted the pro-differentiation effect in Cal27-v25 cells (P<0.05). TACC1v25 overexpression inhibited cell invasion and migration, but similarly, ATRA-mediated RARα reversed these effects and counteracted the downregulated vimentin and p-AKT expression (P<0.05). Conclusions: TACC1v25 may be involved in cell differentiation, invasion, and migration in HNSCC cells, and the dissociation of activated RARα from TACC1v25 might partially counteract the effects of TACC1v25 in HNSCCs. It is possible that ATRA induces conformational changes and/or promotes nuclear translocation of RARα, which in turn reduces its interaction with TACC1v25 and modulates the downstream transcriptional effects. This may provide new ideas for treating HNSCCs.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.